Current Status and Future Prospects of Aromatase Inhibitors in Breast Cancer Treatment
Author Information
Author(s): P.E. L0nning, M. Dowsett, T.J. Powles
Primary Institution: Royal Marsden Hospital, London, and Sutton, UK
Hypothesis
Can aromatase inhibitors effectively reduce estrogen stimulation in breast cancer treatment?
Conclusion
Aminoglutethimide and other aromatase inhibitors show promise in treating advanced breast cancer, but they come with side effects and varying efficacy.
Supporting Evidence
- Aminoglutethimide has been shown to cause response rates similar to surgical adrenalectomy.
- Clinical trials indicate that 4-hydroxyandrostenedione is effective in inducing clinical remission.
- New aromatase inhibitors are being developed to reduce side effects compared to existing treatments.
Takeaway
Aromatase inhibitors help treat breast cancer by lowering estrogen levels, but they can cause side effects like drowsiness and skin rashes.
Methodology
The article reviews various studies and clinical trials on the effectiveness of aromatase inhibitors in breast cancer treatment.
Potential Biases
Potential bias in reporting the efficacy and side effects of different aromatase inhibitors.
Limitations
The article does not provide specific data on patient demographics or detailed statistical analyses.
Want to read the original?
Access the complete publication on the publisher's website